Relationship between the anti-inflammatory properties of salmeterol/fluticasone and the expression of CD4+CD25+Foxp3+ regulatory T cells in COPD

Respiratory Research

Volumn 12, Issue , 2011, Pages

  Yang, Li ^a   Ma, Qian li ^a   Yao, Wei ^a   Zhang, Qiao ^a   Chen, Hua ping ^a   Wang, Guan song ^a   Wang, Chang zheng ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Chronic obstructive pulmonary disease; Inflammatory mediators; Salmeterol and fluticasone propionate; T lymphocytes

Indexed keywords

CD4 ANTIGEN; FLUTICASONE PROPIONATE PLUS SALMETEROL; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 8; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; ANDROSTANE DERIVATIVE; ANTIINFLAMMATORY AGENT; BRONCHODILATING AGENT; CYTOKINE; DRUG DERIVATIVE; FLUTICASONE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; IL2RA PROTEIN, HUMAN; SALBUTAMOL; SALMETEROL;

ADULT; AGED; ANTIGEN EXPRESSION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DRUG EFFECT; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FORCED EXPIRATORY VOLUME; HUMAN; INHALER; LYMPHOCYTE; MALE; MONOCYTE; NEUTROPHIL COUNT; REGULATORY T LYMPHOCYTE; SPUTUM ANALYSIS; STATISTICAL ANALYSIS; CLINICAL TRIAL; GENE EXPRESSION REGULATION; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ALBUTEROL; ANDROSTADIENES; ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD4; BRONCHODILATOR AGENTS; CYTOKINES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME;

EID: 80055012833     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-12-142     Document Type: Article

References (47)

1. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176:532-555. 10.1164/rccm.200703-456SO, 17507545.
2. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004, 364:709-721. 10.1016/S0140-6736(04)16900-6, 15325838.
3. Rytilä P, Plataki M, Bucchieri F, Uddin M, Nong G, Kinnula VL, Djukanovic R. Airway neutrophilia in COPD is not associated with increased neutrophil survival. Eur Respir J 2006, 28:1163-1169. 10.1183/09031936.00149005, 16971404.
4. Cosio MG, Marina S, Alvar A. Immunologic Aspects of Chronic Obstructive Pulmonary Disease. N Engl J Med 2009, 360:2445-2454. 10.1056/NEJMra0804752, 19494220.
5. Turato G, Di Stefano A, Maestrelli P, Turato G, Di Stefano A, Maestrelli P, Mapp CE, Ruggieri MP, Roggeri A, Fabbri LM, Saetta M. Effect of smoking cessation on airway inflammation in chronic bronchitis. Am J Respir Crit Care Med 1995, 152:1262-1267.
6. Rutgers SR, Postma DS, ten Hacken NH, Kauffman HF, van Der Mark TW, Koëter GH, Timens W. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 2000, 55:12-18. 10.1136/thorax.55.1.12, 1745599, 10607796.
7. Gadgil A, Duncan SR. Role of T-lymphocytes and pro-inflammatory mediators in the pathogenesis of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2008, 3:531-541. 2650590, 19281072.
8. Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol 2008, 9:239-44. 3075612, 18285775.
9. Jiang H, Chess L. An integrated view of suppressor T cell subsets in immunoregulation. J Clin Invest 2004, 114:1198-1208. 524238, 15520848.
10. Lee SH, Goswami S, Grudo A, Song LZ, Bandi V, Goodnight-White S, Green L, Hacken-Bitar J, Huh J, Bakaeen F, Coxson HO, Cogswell S, Storness-Bliss C, Corry DB, Kheradmand F. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med 2007, 13:567-569. 10.1038/nm1583, 17450149.
11. Xiong XZ, Jin Y, Zhou Q, Zhang XJ, Du W, Liu W, Huang SA. Correlation between FoxP3+ regulatory T cells and chronic obstructive pulmonary disease. Zhonghua Yi Xue Za Zhi 2008, 88:471-474.
12. Welte T. Optimising treatment for COPD - new strategies for combination therapy. Int J Clin Pract 2009, 63:1136-1149. 10.1111/j.1742-1241.2009.02139.x, 2739483, 19624783.
13. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003, 361:449-456. 10.1016/S0140-6736(03)12459-2, 12583942.
14. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003, 21:74-81. 10.1183/09031936.03.00031402, 12570112.
15. Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, Shah T. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002, 166:1084-1091. 10.1164/rccm.2112055, 12379552.
16. Barnes NC, Qiu YS, Pavord ID, Parker D, Davis PA, Zhu J, Johnson M, Thomson NC, Jeffery PK, . SCO30005 Study Group Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006, 173:736-743. 10.1164/rccm.200508-1321OC, 16424444, SCO30005 Study Group.
17. Pin I, Gibson PG, Kolendowicz R, Girgis-Gabardo A, Denburg JA, Hargreave FE, Dolovich J. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax 1992, 47:25-29. 10.1136/thx.47.1.25, 463545, 1539140.
18. Efthimiadis A, Spanevello A, Hamid Q, Kelly MM, Linden M, Louis R, Pizzichini MM, Pizzichini E, Ronchi C, Van Overvel F, Djukanović R. Methods of sputum processing for cell counts, immunocytochemistry and in situ hybridisation. Eur Respir J Suppl 2002, 37:19s-23s.
19. Liu SF, Chin CH, Wang CC, Lin MC. Correlation between serum biomarkers and BODE index in patients with stable COPD. Respirology 2009, 14:999-1004. 10.1111/j.1440-1843.2009.01608.x, 19740260.
20. Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT, Yates JC, Willits LR, Vestbo J. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009, 10:59. 2714501, 19566934.
21. Chung KF. Salmeterol/fluticasone combination in the treatment of COPD. Int J Chron Obstruct Pulmon Dis 2006, 1:235-242. 10.2147/copd.2006.1.3.235, 2707153, 18046860.
22. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008, 178:332-338. 10.1164/rccm.200712-1869OC, 18511702.
23. Zheng JP, Yang L, Wu YM, Chen P, Wen ZG, Huang WJ, Shi Y, Wang CZ, Huang SG, Sun TY, Wang GF, Xiong SD, Zhong NS. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD. Chest 2007, 132:1756-1763. 10.1378/chest.06-3009, 17951625.
24. Gómez FP, Rodriguez-Roisin R. Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines for chronic obstructive pulmonary disease. Curr Opin Pulm Med 2002, 8:81-86. 10.1097/00063198-200203000-00001, 11845001.
25. Perng DW, Tao CW, Su KC, Tsai CC, Liu LY, Lee YC. Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiotropium in COPD. Eur Respir J 2009, 33:778-784. 10.1183/09031936.00115308, 19129278.
26. Bourbeau J, Christodoulopoulos P, Maltais F, Yamauchi Y, Olivenstein R, Hamid Q. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax 2007, 62:938-943. 10.1136/thx.2006.071068, 2117108, 17557771.
27. Mortaz E, Rad MV, Johnson M, Raats D, Nijkamp FP, Folkerts G. Salmeterol with fluticasone enhances the suppression of IL-8 release and increases the translocation of glucocorticoid receptor by human neutrophils stimulated with cigarette smoke. J Mol Med (Berl) 2008, 86:1045-1056.
28. Lindley I, Aschauer H, Seifert JM, Lam C, Brunowsky W, Kownatzki E, Thelen M, Peveri P, Dewald B, von Tscharner V, et al. Synthesis and expression in Escherichia coli of the gene encoding monocyte-derived neutrophil-activating factor: biological equivalence between natural and recombinant neutrophil-activating factor. Proc Natl Acad Sci USA 1988, 85:9199-9203. 10.1073/pnas.85.23.9199, 282706, 3057503.
29. Stockley RA. Neutrophils and the pathogenesis of COPD. Chest 2002, 121:151S-155S. 10.1378/chest.121.5_suppl.151S, 12010844.
30. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997, 155:542-548.
31. Churg A, Dai J, Tai H, Xie C, Wright JL. Tumor necrosis factor-alpha is central to acute cigarette smoke-induced inflammation and connective tissue breakdown. Am J Respir Crit Care Med 2002, 166:849-854. 10.1164/rccm.200202-097OC, 12231496.
32. Mukhopadhyay S, Hoidal JR, Mukherjee TK. Role of TNFalpha in pulmonary pathophysiology. Respir Res 2006, 7:125. 10.1186/1465-9921-7-125, 1613248, 17034639.
33. Laan M, Cui ZH, Hoshino H, Lötvall J, Sjöstrand M, Gruenert DC, Skoogh BE, Lindén A. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J Immunol 1999, 162:2347-2352.
34. Jones CE, Chan K. Interleukin-17 stimulates the expression of interleukin-8, growth-related oncogene-alpha, and granulocyte-colony-stimulating factor by human airway epithelial cells. Am J Respir Cell Mol Biol 2002, 26:748-753.
35. Prause O, Bozinovski S, Anderson GP, Lindén A. Increased matrix metalloproteinase-9 concentration and activity after stimulation with interleukin-17 in mouse airways. Thorax 2004, 59:313-317. 10.1136/thx.2003.008854, 1763825, 15047951.
36. Di Stefano A, Caramori G, Gnemmi I, Contoli M, Vicari C, Capelli A, Magno F, D'Anna SE, Zanini A, Brun P, Casolari P, Chung KF, Barnes PJ, Papi A, Adcock I, Balbi B. T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients. Clin Exp Immunol 2009, 157:316-324. 10.1111/j.1365-2249.2009.03965.x, 2730858, 19604272.
37. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT, Chance PF, Ochs HD. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001, 27:20-21. 10.1038/83713, 11137993.
38. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003, 4:330-336.
39. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004, 200:277-285. 10.1084/jem.20040165, 2211983, 15280421.
40. Lin YL, Shieh CC, Wang JY. The functional insufficiency of human CD4+CD25 high T-regulatory cells in allergic asthma is subjected to TNF-alpha modulation. Allergy 2008, 63:67-74.
41. Karagiannidis C, Akdis M, Holopainen P, Woolley NJ, Hense G, Rückert B, Mantel PY, Menz G, Akdis CA, Blaser K, Schmidt-Weber CB. Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. J Allergy Clin Immunol 2004, 114:1425-1433. 10.1016/j.jaci.2004.07.014, 15577848.
42. Girtsman T, Jaffar Z, Ferrini M, Shaw P, Roberts K. Natural Foxp3(+) regulatory T cells inhibit Th2 polarization but are biased toward suppression of Th17-driven lung inflammation. J Leukoc Biol 2010, 88:537-546. 10.1189/jlb.0110044, 2924601, 20495073.
43. Jaffar Z, Ferrini ME, Girtsman TA, Roberts K. Antigen-specific Treg regulate Th17-mediated lung neutrophilic inflammation, B-cell recruitment and polymeric IgA and IgM levels in the airways. Eur J Immunol 2009, 39:3307-3314. 10.1002/eji.200939498, 2849980, 19830731.
44. de Latour RP, Visconte V, Takaku T, Wu C, Erie AJ, Sarcon AK, Desierto MJ, Scheinberg P, Keyvanfar K, Nunez O, Chen J, Young NS. Th17 immune responses contribute to the pathophysiology of aplastic anemia. Blood 2010, 116:4175-4184. 10.1182/blood-2010-01-266098, 20733158.
45. Huber S, Gagliani N, Esplugues E, O'Connor W, Huber FJ, Chaudhry A, Kamanaka M, Kobayashi Y, Booth CJ, Rudensky AY, Roncarolo MG, Battaglia M, Flavell RA. Th17 cells express interleukin-10 receptor and are controlled by Foxp3- and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner. Immunity 2011, 34:554-565. 10.1016/j.immuni.2011.01.020, 3113617, 21511184.
46. Ye ZJ, Zhou Q, Zhang JC, Li X, Wu C, Qin SM, Xin JB, Shi HZ. CD39+ regulatory T cells suppress generation and differentiation of Th17 cells in human malignant pleural effusion via a LAP-dependent mechanism. Respir Res 2011, 12:77. 10.1186/1465-9921-12-77, 3120670, 21663645.
47. Lane N, Robins RA, Corne J, Fairclough L. Regulation in chronic obstructive pulmonary disease: the role of regulatory T-cells and Th17 cells. Clin Sci (Lond) 2010, 119:75-86.